Allarity Therapeutics Inc...

1.01
-0.04 (-3.81%)
At close: Feb 11, 2025, 3:59 PM
1.02
0.49%
After-hours Feb 11, 2025, 06:31 PM EST
undefined%
Bid 1.01
Market Cap 4.50M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 5449.42
PE Ratio (ttm) n/a
Forward PE n/a
Analyst n/a
Ask 1.02
Volume 1,459,974
Avg. Volume (20D) 1,825,286
Open 1.05
Previous Close 1.05
Day's Range 0.99 - 1.08
52-Week Range 0.90 - 264.00
Beta undefined

About ALLR

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microt...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 21, 2021
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ALLR
5 months ago
+18.4%
Allarity Therapeutics shares are trading higher. T... Unlock content with Pro Subscription
5 months ago
+10.85%
Allarity Therapeutics shares are trading lower. The company implemented a 1-for-30 reverse stock split to regain Nasdaq listing compliance.